ArticleBioinformation2026
DFDBA with or without allogenic human dental pulp derived mesenchymal stem cells in treatment of mandibular class II furcation defects.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is a challenging task to regenerate the periodontium at the furcation defect. Tissue engineering techniques using stem cells have gained importance in medical field in recent years. Various methods are tried to treat furcation defects. Therefore, it is of interest to assess DFDBA with or without allogenic human dental pulp derived mesenchymal stem cells in treatment of mandibular class II furcation defects. Hence, 28 systemically healthy individuals with at least one mandibular class II furcation defect were divided into 2 groups. Group A (n=14) patients were treated with DFDBA alone and Group B (n= 14) were treated with combination of DFBDA and allogenic dental pulp derived mesenchymal stem cells. Clinical parameters i.e., vertical relative attachment level (V-RAL), vertical probing depth (VPD), horizontal probing depth (HPD) and gingival recession (GR) were recorded at baseline and 6-months post-operatively. DPSCs with DFDBA did not show any statistical significance in both clinical and hard tissue outcome parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.